Zealand Pharma's Zeydovio wins European Commission nod for short bowel syndrome
Zealand Pharma says the European Commission approved Zeydovio (glepaglutide) for short bowel syndrome in the EU and three EEA countries.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Zealand Pharma A/S has announced that the European Commission granted marketing authorization for Zeydovio, the brand name of glepaglutide. The approval applies to adult patients with short bowel syndrome and covers the European Union as well as Iceland, Liechtenstein and Norway, according to reports from Reuters and TradingView.
The company is in talks about commercial partnerships for the drug. Its U.S. Phase 3 study, EASE-5, is still underway, and the announcement includes no sales forecasts, launch dates or financial terms for any potential deal.
why it matters
European approval is an important step for a late-stage asset. Investors, however, will want to see a commercial partner, launch details and EASE-5 results before judging future revenue. The announcement contains no sales estimates.
market impact
Zealand Pharma shares: EU approval supports the company's outlook, though revenue is still unconfirmed
- Zealand Pharma shares pressure up — European regulatory approval removes a hurdle for sales there
tags
instruments
sources
- Zealand Pharma Announces EU Approval Of Zeydovio — Reuters, 13 November 2026 at 15:01 UTC
- Zealand Pharma A/S (ZEAL) Wins EU Approval for Zeydovio in Short Bowel Syndrome — TradingView, 13 November 2026 at 14:58 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗